115 related articles for article (PubMed ID: 20653657)
1. Testosterone may speed up the growth of prostate cancer due to aromatase activity.
Friedman AE
BJU Int; 2010 Aug; 106(3):434. PubMed ID: 20653657
[No Abstract] [Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
Morales A
BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
[TBL] [Abstract][Full Text] [Related]
4. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
Morales A; Black AM; Emerson LE
BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
Halland A; Jønler M; Pedersen KV
Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
[TBL] [Abstract][Full Text] [Related]
6. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
Kaufman J
Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
9. 54-year-old man with breast cancer after prolonged testosterone therapy.
Sorscher S
Clin Adv Hematol Oncol; 2005 Sep; 3(9):713. PubMed ID: 16224445
[No Abstract] [Full Text] [Related]
10. Testosterone therapy in the ageing male: what about the prostate?
Schultheiss D; Machtens S; Jonas U
Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
[TBL] [Abstract][Full Text] [Related]
11. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole.
Rhoden EL; Morgentaler A
Int J Impot Res; 2004 Feb; 16(1):95-7. PubMed ID: 14963480
[TBL] [Abstract][Full Text] [Related]
12. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
Meza J; Weaver K; Martin S
Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
[No Abstract] [Full Text] [Related]
13. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
Gould DC; Feneley MR; Kirby RS
BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
[TBL] [Abstract][Full Text] [Related]
14. [Androgen deficiency in males and its correction in respect to pathogenesis of prostatic cancer].
Mazo EB; Grigor'ev ME; Konorev VA; Ermisheva OM
Urologiia; 2008; (3):57-8, 60-2. PubMed ID: 18669351
[No Abstract] [Full Text] [Related]
15. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
Gould DC; Kirby RS
Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
[TBL] [Abstract][Full Text] [Related]
17. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
Ebert T; Jockenhövel F; Morales A; Shabsigh R
Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
[TBL] [Abstract][Full Text] [Related]
18. Safety of androgen therapy in men with prostate cancer.
Rajan P; Tharakan T; Chen R
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer in men using testosterone supplementation.
Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
[TBL] [Abstract][Full Text] [Related]
20. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
Rhoden EL; Riedner CE; Morgentaler A
J Urol; 2008 May; 179(5):1741-4. PubMed ID: 18343420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]